Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

Key Points

• HC Wainwright cut Sutro Biopharma’s Q3 2026 forecast to a loss of $2.38 per share from $2.32, while maintaining a “Buy” rating and $50 price target. The firm projects continued losses through 2030.
• Sutro’s latest quarterly results missed expectations, reporting a $2.33-per-share loss versus the $2.19 consensus and revenue of $9.84 million versus $11.96 million expected.
• Despite the earnings miss, analyst sentiment remains broadly positive: the stock has an average “Buy” rating and a $47.30 consensus price target, with targets as high as $60.

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Sutro Biopharma in a report issued on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($2.38) per share for the quarter, down from their previous estimate of ($2.32). HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($9.06) per share. HC Wainwright also issued estimates for Sutro Biopharma's Q4 2026 earnings at ($2.46) EPS, FY2027 earnings at ($4.69) EPS, FY2028 earnings at ($7.07) EPS, FY2029 earnings at ($4.94) EPS and FY2030 earnings at ($5.09) EPS.

Other equities research analysts have also issued reports about the stock. Stifel Nicolaus set a $48.00 price objective on shares of Sutro Biopharma and gave the company a "buy" rating in a report on Friday, August 7th. Truist Financial started coverage on shares of Sutro Biopharma in a research note on Thursday, June 11th. They issued a "buy" rating and a $50.00 price target on the stock. Citigroup restated a "market outperform" rating on shares of Sutro Biopharma in a report on Thursday. Wedbush reaffirmed an "outperform" rating and set a $60.00 price target on shares of Sutro Biopharma in a research report on Thursday. Finally, Lifesci Capital upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $47.30.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $21.31 on Friday. Sutro Biopharma has a fifty-two week low of $7.15 and a fifty-two week high of $43.85. The company's 50-day simple moving average is $26.98 and its 200-day simple moving average is $25.99. The stock has a market capitalization of $353.11 million, a P/E ratio of -1.93 and a beta of 1.55.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($2.33) earnings per share for the quarter, missing analysts' consensus estimates of ($2.19) by ($0.14). The firm had revenue of $9.84 million during the quarter, compared to analysts' expectations of $11.96 million.

Institutional Trading of Sutro Biopharma

Large investors have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP increased its holdings in shares of Sutro Biopharma by 2.0% in the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company's stock valued at $2,709,000 after buying an additional 60,000 shares in the last quarter. UBS Group AG boosted its holdings in shares of Sutro Biopharma by 14.0% during the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company's stock worth $1,602,000 after buying an additional 226,955 shares during the period. AQR Capital Management LLC boosted its position in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock valued at $859,000 after acquiring an additional 1,206,330 shares during the period. Affinity Asset Advisors LLC raised its position in shares of Sutro Biopharma by 42.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company's stock valued at $26,642,000 after buying an additional 321,137 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in Sutro Biopharma in the first quarter worth about $19,956,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma News Roundup

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $60 price target, while HC Wainwright reiterated its “Buy” rating and $50 target. These targets imply substantial potential upside if Sutro’s pipeline advances successfully. Benzinga analyst coverage
• Positive Sentiment: HC Wainwright improved its longer-term loss forecasts for fiscal 2027 through 2030. Estimated losses were narrowed to $4.69 per share for 2027, $7.07 for 2028, $4.94 for 2029 and $5.09 for 2030, suggesting expectations for better future operating performance than previously modeled.
• Neutral Sentiment: Citizens JMP lowered its price target from $41 to $34 but retained a “Market Outperform” rating. The reduced target reflects more cautious valuation assumptions, although the firm still sees meaningful upside from current levels. Citizens JMP price target update
• Negative Sentiment: HC Wainwright lowered its projected third- and fourth-quarter 2026 losses to $2.38 and $2.46 per share, respectively, compared with prior estimates of $2.32 for each quarter. The revisions indicate higher expected near-term expenses and extend the company’s path to profitability.
• Negative Sentiment: Sutro’s recent quarterly results missed expectations, with a loss of $2.33 per share versus the $2.19 consensus estimate and revenue of $9.84 million versus estimates of $11.96 million. The company’s clinical update on the STRO-004 Phase 1 study also raised investor concerns, contributing to selling pressure. Why Sutro Biopharma stock is falling

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source